Estimating clinical trial bleeding events using electronic health record data

被引：0
作者：
Eisenstein E.L. [1 ]
Wojdyla D. [1 ]
Kong D.F. [1 ]
机构：
[1] Duke Clinical Research Institute, 2400 Pratt St., Durham, NC
来源：
Studies in Health Technology and Informatics | 2019年 / 257卷
关键词：
clinical trial; electronic health record; endpoint major bleed;
D O I：
10.3233/978-1-61499-951-5-92
中图分类号：
学科分类号：
摘要：
Clinical trials conducted for regulatory approval may include outcomes that are informative but not routinely collected in clinical practice. This situation can be problematic when pragmatic clinical trials (PCT) seek to use electronic health record (EHR) data to test the effectiveness of medical products and services in actual practice settings. We use TIMI bleeding events to illustrate how a complex clinical trial endpoint can be implemented using EHR data. While we were able to demonstrate that our EHR-defined bleeding events were associated with differences in patient clinical outcomes, we are not confident that these measurements could be replicated in other locations with consistent reliability and validity. We believe the development of PCT endpoint definitions is an important issue that should be addressed by medical and informatics professional societies, regulators and the medical products industry. © 2019 American Psychological Association Inc. All rights reserved.
引用
收藏
页码：92 / 97
页数：5
相关论文
共 9 条
  • [1] Loudon K., Treweek S., Sullivan F., Et al., The PRECIS-2 tool: Designing trials that are fit for purpose, BMJ, 350, (2015)
  • [2] Levine G.N., Bates E.R., Bittl J.A., Et al., A guideline focused update on the duration of dual antiplatelet therapy in patients with coronary artery disease a report of the American college of cardiology/American Heart Association task force on clinical practice guidelines, J of Am Coll Cardiol, 68, 10, pp. 1082-1115, (2016)
  • [3] Rao S.V., O'Grady K., Pieper K.S., Et al., A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes, J Am Coll Cardiol., 47, 4, pp. 809-816, (2006)
  • [4] Guimaraes P.O., Krishnamoorthy A., Kaltenbach L.A., Et al., Accuracy of medical claims for identifying cardiovascular bleeding events after myocardial infarction: A secondary analysis of the TRANSLATE-ACS Study, JAMA Cardiol., 2, 7, pp. 750-757, (2017)
  • [5] Califf R.M., Harrell F.E., Lee K.L., Et al., The evolution of medical and surgical therapy for coronary artery disease A 15-year perspective, JAMA, 261, pp. 2077-2086, (1989)
  • [6] Fortin D.F., Califf R.M., Pryor D.B., Mark D.B., The way of the future redux, American Journal of Cardiology, 76, pp. 177-182, (1995)
  • [7] Rosati R.A., McNeer J.F., Starmer C.F., Mittler B.S., Morris J.J., Wallace A.G., A new information system for medical practice, Archives of Internal Medicine, 135, pp. 1017-1024, (1975)
  • [8] Eisenstein E.L., Kong D.F., Cowper P.A., Bae J.P., Ramaswamy K., Anstrom K.J., Nonfatal myocardial infarction and long-term outcomes in coronary artery disease, Am Heart J, 163, pp. 95-103, (2012)
  • [9] Mehran R., Rao S.V., Bhatt D.L., Et al., Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the Bleeding Academic Research Consortium, Circulation., 123, (2011)
1